Safety and immune response study of YKYY025 RSV vaccine
Part of Infections, Lungs & breathing clinical trials.
This study tests a new RSV vaccine called YKYY025 in healthy adults. The main goal is to see if it is safe and to measure how the immune system responds.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 49 years old (for Part 1) or 50 or older (for Part 2).
- You cannot have received an RSV vaccine or been in an RSV vaccine study before.
- You should not have had a confirmed RSV infection in the last 6 months.
- You must not be taking long-term immune-suppressing medicines (like high-dose steroids for 2 weeks or more).
- You may not have a history of heart conditions like myocarditis or pericarditis.
- Women who can get pregnant must use birth control for at least 2 weeks before the shot and until 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new vaccine that may protect babies from a common breathing virus called RSV. It is given to healthy women to see if it is safe and if it helps the body make protection that could be passed to a baby during pregnancy.
This trial tests a new vaccine against respiratory syncytial virus (RSV), a common virus that can cause lung infections. It is for healthy adults aged 18 and older, to see if the vaccine is safe and produces a good immune response.
This study tests an inhaled medication for adults with a respiratory syncytial virus (RSV) infection that causes symptoms like cough or trouble breathing. If you have RSV and these symptoms, this treatment might help you feel better.
This study tests a new vaccine designed to protect against respiratory syncytial virus (RSV), a common virus that can cause serious lung infections. The vaccine is given as a shot, and the study will check how your immune system responds to it.
This trial tests a new RSV vaccine for people aged 60 and above. RSV is a common virus that can cause serious breathing problems in older adults. The study will see if the vaccine is safe and helps protect you from RSV.
This study tests an RSV vaccine in adults aged 18 and older, especially those with chronic health issues like heart or lung disease. It aims to see how safe and effective the vaccine is at preventing RSV infections.
Hear when a new Respiratory Syncytial Virus (RSV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.